Application Information

This drug has been submitted to the FDA under the reference 022545/001.

Names and composition

"TEKAMLO" is the commercial name of a drug composed of ALISKIREN HEMIFUMARATE and AMLODIPINE BESYLATE.

Forms

ApplId/ProductId Drug name Active ingredient Form Strenght
022545/001 TEKAMLO ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE TABLET/ORAL EQ 150MG BASE and EQ 5MG BASE
022545/002 TEKAMLO ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE TABLET/ORAL EQ 150MG BASE and EQ 10MG BASE
022545/003 TEKAMLO ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE TABLET/ORAL EQ 300MG BASE and EQ 5MG BASE
022545/004 TEKAMLO ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE TABLET/ORAL EQ 300MG BASE and EQ 10MG BASE

Similar Active Ingredient

ApplId/ProductId Drug name Active ingredient Form Strenght
022545/001 TEKAMLO ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE TABLET/ORAL EQ 150MG BASE and EQ 5MG BASE
022545/002 TEKAMLO ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE TABLET/ORAL EQ 150MG BASE and EQ 10MG BASE
022545/003 TEKAMLO ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE TABLET/ORAL EQ 300MG BASE and EQ 5MG BASE
022545/004 TEKAMLO ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE TABLET/ORAL EQ 300MG BASE and EQ 10MG BASE

Ask a doctor

A licensed doctor will try to answer your question for free as quickly as possible. Free of charge during the beta period.

Related

Browse by letter
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

© Medications.li 2015-2017 - All rights reserved